Autologous stem cell transplantation in follicular lymphoma: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 104, Issue 1, 2012, Pages 18-28

  Al Khabori, Murtadha ^a,b   De Almeida, John R ^a   Guyatt, Gordon H ^c   Kuruvilla, John ^a   Crump, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYELOABLATIVE AGENT; PREDNISOLONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVERSE OUTCOME; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; DRUG MEGADOSE; EMBASE; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; GENETIC HETEROGENEITY; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHOMA, FOLLICULAR; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SELECTION BIAS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 84855493974     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr450     Document Type: Review

References (36)

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9(7):717-720. (Pubitemid 28394156)
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. (Pubitemid 43053551)
3. Gribben JG. How I treat indolent lymphoma. Blood. 2007;109(11):4617-4626. (Pubitemid 46830597)
4. Ezdinli EZ, Harrington DP, Kucuk O, et al. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer. 1987;60(2):156-160. (Pubitemid 17092248)
5. Jones SE, Grozea PN, Metz EN, et al. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 1979;43(2):417-425. (Pubitemid 9122259)
6. Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006;107(5):1014-1022. (Pubitemid 44321684)
7. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23(10):2215-2223. (Pubitemid 46218713)
8. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
9. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27(10):1607-1614.
10. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105(10):3817-3823. (Pubitemid 40656123)
11. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-4013.
12. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(9):2667-2674. (Pubitemid 39434946)
13. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006;108(8):2540-2544.
14. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301. (Pubitemid 44794222)
15. Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008;45(3) (Suppl. 2):S2-S6.
16. Illidge T, Chan C. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma. 2008;49(7):1263-1273. (Pubitemid 352022536)
17. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol. 2008;66(3):248-261.
18. Higgins J, Altman D. Chapter 8: assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834. (Pubitemid 28562978)
21. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
22. Cohen JA. Coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37-46.
23. Deeks J, Higgins J, Altman D. Chapter 9: analysing data undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, UK: John Wiley & Sons Ltd.; 2008:243-296.
24. Hermans J, Krol AD, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995;86(4):1460-1463.
25. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. (Pubitemid 39166497)
26. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman D, eds. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London, UK: BMJ Publication Group; 2001:285-312.
27. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. (Pubitemid 351632017)
28. NCI-V89-0192. Phase III Comparison of Consolidation with Extended Field Radiotherapy vs Autologous Bone Marrow Therapy for Patients with Advanced Low-Grade Non-Hodgkin's Lymphoma in First CR Following ProMACE-MOPP. http://www.cancer.gov/clinicaltrials/search/view?cdrid=76136&version= HealthProfessional&protocolsearchid=7801137. Accessed October 21, 2011.
29. NCT00003152. Marrow-Ablative Chemo-Radiotherapy and Autologous Stem Cell Transplantation Followed by Interferon-Alpha Maintenance Treatment Versus Interferon-Alpha Maintenance Treatment Alone After a Chemotherapy-Induced Remission in Patients With Stages III or IV Follicular Non-Hodgkin's Lymphoma. A Prospective, Randomized, Phase III Clinical Trial. www.Clinicaltrials.gov. Accessed March 8, 2009.
30. Meckenstock G, Kobbe G, Kronenwett R, et al. First line treatment of advanced follicular lymphoma comparing fludarabine/mitoxantrone and high-dose chemotherapy, each combined with CD20-antibody rituximab. In: Anonymous, ed. Onkologie; 2005:153.
31. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995-1001.
32. Lenz G, Unterhalt M, Haferlach T, et al. Significant increase of secondary myelodysplasia and acute myeloid leukemia after myeloablative radiochemotherapy followed by autologous stem cell transplantation in indolent lymphoma patients: Results of a prospective randomized study for the GLSG. Blood. 2003;102(11):986a-987a.
33. Sun X, Briel M, Busse JW, et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials. Trials. 2009;10(1):101.
34. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009;610-618.
35. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. (Pubitemid 40223656)
36. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1(2):121-129. (Pubitemid 13146129)